Meal timing may matter for new sickle cell drug
NCT ID NCT06433661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a high-fat meal changes the amount of the drug etavopivat in the blood of 16 healthy adults. Participants took a single dose of etavopivat after eating a high-fat meal and on an empty stomach on separate days. The goal is to understand if food affects how the drug is absorbed, which can guide future dosing for people with sickle cell disease or thalassemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- etavopivat
- What this could lead to
- If successful, this study could help determine the best way to take etavopivat (with or without food) for future sickle cell disease and thalassemia treatments.
- What could go wrong
- This is a small, early-phase study in healthy volunteers, not patients. Results may not directly predict how the drug works in people with the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS SICKLE CELL DISEASE, THALASSEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON-Salt Lake City
Salt Lake City, Utah, 84124, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.